Literature DB >> 1836485

Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor.

C W Shearman1, D Pollock, G White, K Hehir, G P Moore, E J Kanzy, R Kurrle.   

Abstract

Completely humanized antibodies with specificity for the human alpha/beta TCR have been produced by genetic engineering. The L and H chain V region exons encoding the murine mAb BMA 031 CD regions and human EU framework regions were synthesized and replaced into previously isolated genomic fragments. These fragments were inserted into mammalian expression vectors containing the human kappa and gamma 1 C region exons. Two variants were constructed each containing selected BMA 031 amino acids within the human frameworks. The humanized genes were transfected into Sp2/0 hybridoma cells by electroporation and transfectomas secreting humanized antibody were isolated. Levels of antibody expression up to 7 pg/cell/24 h were obtained. The humanized antibody, BMA 031-EUCIV2, competed poorly with murine BMA 031 for binding to T cells. BMA 031-EUCIV3, however, bound specifically to T cells and competed effectively with both the murine BMA 031 antibody and a previously constructed chimeric BMA 031 antibody for binding to these cells. The relative affinity of BMA 031-EUCIV3 was about 2.5 times lower than BMA 031. The ability to promote antibody dependent cell-mediated cytolysis was significantly enhanced with the engineered antibodies as compared to murine BMA 031. Humanized BMA 031 is a clinically relevant, genetically engineered antibody with potential uses in transplantation, graft vs host disease, and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836485

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Generation and characterization of high affinity humanized fab against hepatitis B surface antigen.

Authors:  Ashutosh Tiwari; Durgashree Dutta; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  Mol Biotechnol       Date:  2009-03-27       Impact factor: 2.695

2.  Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.

Authors:  M E Verhoeyen; J A Saunders; M R Price; J D Marugg; S Briggs; E L Broderick; S J Eida; A T Mooren; R A Badley
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

3.  Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies.

Authors:  M H Foster; T Kieber-Emmons; M Ohliger; M P Madaio
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

4.  Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

Authors:  Michael Durben; Dominik Schmiedel; Martin Hofmann; Fabian Vogt; Tina Nübling; Elwira Pyz; Hans-Jörg Bühring; Hans-Georg Rammensee; Helmut R Salih; Ludger Große-Hovest; Gundram Jung
Journal:  Mol Ther       Date:  2015-01-12       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.